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Abstract An essential function of the transcription fac-
tors LEF1/TCF4 in cerebral metastases of lung adenocar-
cinomas has been described in mouse models, suggesting a
WNT/b-catenin effect as potential mechanism. Their role
in humans is still unclear, thus we analyzed LEF1, TCF4,
b-catenin, and early stage prognostic markers in 25 adeno-
carcinoma brain metastases using immunohistochemistry
(IHC). IHC revealed nuclear TCF4 in all adenocarcinoma
samples, whereas only 36 % depicted nuclear LEF1 and
nuclear b-catenin signals. Samples with nuclear LEF1 as
well as high TCF4 (????) expression were associated with
a shorter survival (p = 0.01, HR = 6.68), while nuclear
b-catenin had no significant impact on prognosis and did not
significantly correlate with nuclear LEF1. High proliferation
index Ki67 was associated with shorter survival in late-stage
disease (p = 0.03, HR 3.27). Additionally, we generated a
LEF1/TCF4 as well as an AXIN2 signature, the latter as
representative of WNT/b-catenin activity, following a bio-
informatics approach with a gene expression dataset of
cerebral metastases in lung adenocarcinoma. To analyze the
prognostic relevance in primary lung adenocarcinomas, we
applied both signatures to a microarray dataset of 58 primary
lung adenocarcinomas. Only the LEF1/TCF4 signature was
able to separate clusters with impact on survival (p = 0.01,
HR = 0.32). These clusters displayed diverging enrichment
patterns of the cell cycle pathway. In conclusion, our data
show that LEF1/TCF4, but not b-catenin, have prognostic
relevance in primary and cerebrally metastasized human
lung adenocarcinomas. In contrast to the previous in vivo
findings, these results indicate that LEF1/TCF4 act inde-
pendently of b-catenin in this setting.
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Introduction
Lung cancer is the leading cause of cancer death worldwide
due to its aggressive clinical course coupled with a high
frequency of distant metastasis and insufficient treatment
options [1]. In 10–25 % of lung cancer patients, brain
metastases are already present at diagnosis, and a further
40–50 % develop brain metastasis during the course of
treatment. Furthermore, primary lung cancers are respon-
sible for 40–50 % of all brain metastases. Patients with
lung cancer brain metastases have an unfavorable prog-
nosis, since micro-metastases are shielded by the blood
brain barrier and are frequently resistant to radio- and/or
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chemotherapy. However, studies on lung cancer cerebral
metastases are rare due to the lack of preclinical models
and scarceness of histological material. Moreover, clinical
trials often exclude patients with cerebral metastases, thus
the prognosis has not essentially improved over the last
decades [2, 3].
The heterogeneity of primary lung cancers and their
varying biological behavior still remain a challenge to
pathologists and oncologists [4]. Common histological
classification defines two main groups: small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC),
the latter including adeno-, squamous cell, and large cell
carcinoma. This classification does not reflect the differ-
ences in biological and clinical behavior sufficiently. At
least adenocarcinomas, the most frequent lung cancer
subtype, can be further subdivided according to histologi-
cal and molecular features [4]. Moreover, some of the
histological markers in primary lung adenocarcinomas
have prognostic impact. TTF1-negativity as well as a high
proliferation index Ki67 are associated with poor overall
survival in early-stage disease [5–8].
Recent in vivo experiments in a xenograft brain lung
metastasis model postulated a functional role for lymphoid
enhancer factor 1/T cell factor 4 (LEF1/TCF4) in a sub-
group of adenocarcinomas [9]. Both LEF1 and TCF4 are
sequence-specific transcription factors of the high mobility
group (HMG) family. They can utilize at least two mech-
anisms to regulate transcriptional activity. On the one hand,
the LEF/TCF protein family has the capacity to bend DNA
after binding to the minor grove of the double helix. This
architectural alteration is necessary for the subsequent
interaction with other transcription factors to regulate gene
transcription. On the other hand, the members of the LEF/
TCF protein family are the transcriptional effectors of
WNT/b-catenin signaling [10].
Activation of the WNT/b-catenin pathway, also known
as canonical WNT signaling, leads to stabilization of
b-catenin. Subsequently, b-catenin translocates into the
nucleus, where it binds as a co-activator to the LEF/TCF
proteins and regulates transcription of WNT/b-catenin
target genes. Given that b-catenin has no DNA binding
motif, the LEF/TCF proteins are necessary for the tran-
scriptional consequences of WNT/b-catenin signaling.
Apart from WNT signaling through ligand binding, genetic
mutations of b-catenin or the b-catenin degradation com-
plex can also lead to stabilization, cytoplasmic accumula-
tion, nuclear translocation, and binding of b-catenin to
LEF/TCF transcription factors [11].
Recent mouse studies also demonstrated an impact of a
WNT-lung signature on relapse of patients with primary
lung adenocarcinomas [9]. This WNT-lung signature was
derived from a gene expression analysis with the typical
WNT/b-catenin activator WNT3a. A b-catenin gene sig-
nature alone [12] was not predictive in this context [9].
We and others recently demonstrated a potential role for
WNT signaling in brain metastasis of breast cancer patients
[13–15]. Thus, in the present study, we focused on the role
of WNT signaling in brain metastases of lung adenocar-
cinomas, investigating the expression patterns of LEF1,
TCF4, and b-catenin in tissue samples of lung adenocar-
cinoma brain metastases and their impact on patient sur-
vival. Furthermore, following a bioinformatics approach
we generated a LEF1/TCF4 as well as an AXIN2 gene
signature in cerebral metastases and investigated their
prognostic value in a dataset of primary lung adenocarci-
nomas. Moreover, we investigated the prognostic relevance
of TTF1 and Ki67 in brain metastasis samples.
Materials and methods
Patient samples
Forty brain metastasis samples of lung cancers were col-
lected with informed consent during medically indicated
neurosurgical procedures following approval by the local
ethics committee. Twenty-five were defined as lung ade-
nocarcinomas and included into further investigations. This
patient cohort was characterized in terms of demographics,
clinical baseline data, and applied treatment concepts.
Immunohistochemistry (IHC)
For diagnostic purposes, all tissue samples were stained
with antibodies to cytokeratin (CK) 5/6, CK 7, CK 20,
TTF1, chromogranin A, synatophysin, NSE, and Ki67.
Only samples histologically and immunohistochemically
defined as adenocarcinomas of the lung were further
evaluated and stained with the rabbit monoclonal anti-
LEF1 (Cell Signaling Technology, Boston, USA), anti-
TCF4 (Abcam, Cambridge, UK), and mouse anti-b-catenin
antibody (Santa Cruz Biotechnology, Heidelberg, Ger-
many). Nuclear LEF1, TCF4, and b-catenin status were
evaluated independently by at least two researchers.
Nuclear b-catenin and LEF1 expression were classified into
four groups: 0 = 0 %, 1? = 1–25 %, 2? = 25–50 % and
3? [ 50 % of the tumor cells with positive nuclear
staining (Figs. 1, 3). Since nuclear b-catenin and LEF1
expression levels were lower than the TCF4 levels, a dif-
ferent scoring system with five groups was applied for
TCF4 staining to discriminate changes between relatively
high TCF4 expression levels: 0 = 0 %, 1? = 1–33 %,
2? = 33–66 %, 3? = 66–99 % and 4? [ 99 % (Fig. 2).
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RNA isolation
RNA was isolated with a modified Trizol (Invitrogen, Kar-
lsruhe, Germany) method incorporating a DNase (Roche,
Mannheim, Germany) digestion step. Reverse transcription
was performed with the iScript Master Mix (BioRad,
Munich, Germany) as described previously [14, 15].
qRT-PCR
Quantitative PCR was carried out as described previously
[15] with SYBR Advantage reagents (Clontech, Saint-
Germain-en-Laye, France) according to the manufacturer’s
instructions using mRNA specific, intron-spanning primers:
AXIN2-fwd: GGGCCACTTTAAAGAGCAG, AXIN2-rev:
CCTTCATACATCGGGAGCA. All real-time PCRs were
performed using the HT 7900 system (Applied Biosystems,
Frankfurt, Germany). Ct values for AXIN2, b-catenin,
cyclinD1, c-myc, and VEGF-A were calculated using SDS
Software Version 2.1 (Applied Biosystems) and gene
expressions were normalized to GNB2L1 [15].
External microarray datasets
Two Affymetrix U133 Plus 2.0 datasets containing 58 primary
adenocarcinomas of the lung (GSE3141) and 19 brain
metastasis samples of primary adenocarcinomas of the lung
(GSE14108) were retrieved from the NCBI Gene Expression
Omnibus (GEO) data repository [16]. The primary lung can-
cer dataset (GSE3141) contained survival information and
Fig. 1 Nuclear LEF1 expression in brain metastases of adenocar-
cinomas of the lung (IHC): examples of the different LEF1 nuclear
patterns. Nuclear LEF1 expression were classified into four groups:
0 = 0 %, 1? = 1–25 %, 2? = 25–50 % and 3? [50 % of the
tumor cells with positive nuclear staining
Clin Exp Metastasis (2013) 30:471–482 473
123
KRAS mutation status for all samples of early-stage patients;
in contrast, the brain metastases dataset did not contain any
survival information with respect to the stage IV patients.
Statistics and bioinformatics
Survival analysis was performed for overall survival since
first diagnosis of brain metastasis. Events were defined as
cancer-related death; all other events were considered as
censored. Survival data were visualized using Kaplan–
Meier plots and significance was calculated using the Cox
proportional hazards model [17] for univariate and multi-
variate analyses. Normalized gene expression data of all
Affymetrix U133 Plus 2.0 microarrays were log2 trans-
formed. p values \ 0.05 were considered significant.
To establish LEF1/TCF4 and AXIN2-specific gene
signatures, we correlated the expression of selected WNT
target genes (Supplementary Table 1) with LEF1 or TCF4
and AXIN2 expression using Pearson‘s correlation test in
the lung adenocarcinoma brain metastasis dataset
(GSE14108). Genes were assigned to the LEF1/TCF4 or
AXIN2 gene list according to their mean negative and
positive correlations (r C 0.4, r B -0.4).
The resulting gene signatures were used in hierarchical
clustering analyses of the primary lung adenocarcinomas
with complete linkage agglomeration, based on the
Euclidean distance measure. Differences in overall survival
were assessed using Cox proportional hazards regression
models. Differential gene expression analysis between
patient groups identified by the clustering analysis was
Fig. 2 Nuclear TCF4 expression in brain metastases of adenocar-
cinomas of the lung (IHC): examples of the different TCF4 nuclear
patterns. Nuclear TCF4 expression was classified into five groups:
0 = 0 %, 1? = 1–33 %, 2? = 33–66 %, 3? = 66–99 % and
4? [ 99 % of the cells with positive nuclear TCF4 staining
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performed using empirical Bayes-moderated T-statistics
implemented in ‘‘limma’’ [18]. All resulting p-values were
adjusted for multiple testing to control the false discovery
rate (fdr) using the Benjamini-Hochberg correction.
Gene lists for selected signaling pathways were obtained
from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database [19]. Genes were ranked according to the
p-value for differential expression from the microarray
experiments. In order to test for significantly enriched
pathways, a one-sided Wilcoxon rank sum test was per-
formed on the gene ranks for each pathway [20]. All
analyses were performed using the free statistical software
R (version 2.15.1; http://www.r-project.org).
Results
Characterization of the patient cohort
Forty brain metastasis samples of lung cancers were charac-
terized and further classified (see ‘‘Materials and methods’’
section). Twenty-five were defined as adenocarcinomas and
included in further investigations. The others proved to be
squamous cell carcinoma, small cell lung cancer (SCLC) or
unclassifiable and were therefore excluded from this study.
Immunohistochemical markers were stained as described in
the ‘‘Materials and methods’’ section IHC. The patient cohort
was characterized according to the listed parameters in
Table 1. Survival was significantly shorter in the cohort with
secondary organ metastasis (p = 0.02, HR = 3.03). Fur-
thermore the retrospective analysis of radiotherapy
(p = 0.001, HR = 0.13) as well as chemotherapy after sur-
gery (p = 0.005, HR = 0.22) revealed an improved survival
(Table 1). The latter results can most likely be attributed to a
different performance status of the patients, so that some did
not qualify for further post-operative treatment.
High proliferation index was associated with shorter
survival
TTF1 immunostaining was detected in 17/25 (68 %) ade-
nocarcinoma brain metastases. The proliferation index
Ki67 ranged from 3 to 40. Seventeen out of 25 samples
Table 1 Univariate analysis of clinicopathological baseline data affecting survival






Age Median [95 % CI] 61
95 % CI [47.8–82.4]
Age C61: 1.89
95 % CI [0.78–4.57]
0.1511
Sex Female (%) 36.0 % (9/25) Gender male: 2.36
95 % CI [0.82–6.79]
0.1035
Male (%) 64.0 % (16/25)
Cerebral metastases present
at diagnosis of lung cancer
Yes (%) 72.0 % (18/25) Present at diagnosis: 1.03
95 % CI [0.37–2.88]
0.9548
No (%) 28.0 % (7/25)
Number of cerebral metastases Solitary (%) 60.0 % (15/25) Multiple metastases: 0.65
95 % CI [0.26–1.64]
0.3586
[ 1 (%) 40.0 % (10/25)
Secondary organ metastasis
at diagnosis of brain metastasis
Yes (%) 56.0 % (14/25) Secondary organ metastases: 3.03
95 % CI [1.16–7.95]
0.0178
No (%) 44.0 % (11/25)
CT Chemotherapy before brain surgery Yes (%) 16.7 % (4/24a) CT before surgery: 1.50
95 % CI [0.45–5.30]
0.5240
No (%) 83.3 % (20/24a)
RT Radiotherapy of the brain
after brain surgery
Yes (%) 87.5 % (21/24a) RT yes: 0.13
95 % CI [0.03–0.54]
0.0010
No (%) 12.5 % (3/24a)
CT Chemotherapy after brain surgery Yes (%) 66.7 % (12/18a) CT after surgery: 0.22
95 % CI [0.07–0.70]
0.0055
No (%) 33.3 % (6/18a)
TTF1 Negative B3 (%) 32.0 % (8/25) TTF1 positive: 0.57
95 % CI [0.21–1.52]
0.2565
Positive [3 (%) 68.0 % (17/25)
Ki67 Low \10 (%) 32.0 % (8/25) Ki67 high: 3.27
95 % CI [1.03–10.34]
0.03476
High C10 (%) 68.0 % (17/25)
Patient cohort was characterized according to listed parameters in the first column. Type of classification and distribution within the cohort as
well as impact on survival including p value (log-rank) is given for each parameter
a Cases where not for all patients baseline data was available
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(68 %) demonstrated a proliferation index of Ki67 [ 10 %
positive staining. Survival was significantly shorter in the
Ki67 [ 10 % expressing subgroup of brain metastasis
(p = 0.03, HR = 3.27) (Table 1 ; Fig. 4a). TTF1 did not
have significantly impact survival (p = 0.26, HR = 0.57).
However, TTF1-negativity correlated with a higher pro-
liferation index Ki67 [ 10 % (p = 0.02, r = -0.47, 95 %
CI [-0.73 to -0.09]).
Fig. 3 Nuclear b-catenin expression in brain metastases of adeno-
carcinomas of the lung (IHC): examples of the different nuclear b-
catenin patterns. Nuclear b-catenin expression was classified into four
groups: 0 = 0 %, 1? = 1–25 %, 2? = 25–50 % and 3? [ 50 % of
the tumor cells with positive nuclear staining. Cytoplasmic and
membrane staining did not enter the grading scheme
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A subgroup of lung adenocarcinoma brain metastases
expressed nuclear LEF1
Nuclear LEF1 immunostaining was detected in 9/25 (36 %)
adenocarcinoma brain metastases. Apart from one sample
graded 2?, all the others were graded 1? (see ‘‘Materials and
methods’’ section) (Fig. 1). Nuclear TCF4 was expressed in
all samples (100 %). Three samples were graded 2?, fifteen
samples 3?, and seven samples 4? (Fig. 2). Nuclear local-
ization of b-catenin was detectable in 9/25 (36 %) samples
and ranged from 1? in seven samples to one sample graded
2? and 3?, respectively (Fig. 3). Unexpectedly, nuclear
localization of LEF1 did not correlate with nuclear b-catenin
expression (p = 0.53, r = 0.13, 95 % CI [-0.28 to 0.49]). In
contrast, nuclear LEF1 correlation with TTF1-negative
samples was near the borderline of significance (p = 0.06,
r = -0.38, 95 % CI [-0.66 to 0.02]). A similar tendency
with Ki67 [ 10 % (p = 0.1, r = 0.34, 95 % CI [-0.07 to
0.65]) could be observed, while nuclear b-catenin neither
correlated with TTF1 (p = 0.92, r = -0.02, 95 %
CI [-0.41 to 0.38]) nor with Ki67 expression (p = 0.92,
r = -0.02, 95 % CI [-0.41 to 0.38]).
Significantly shorter survival was observed
in the LEF1/TCF4 subgroup
Neither TCF4 (p = 0.73, HR = 1.19, 95 % CI [0.45 to
3.1]) nor LEF1 (p = 0.35, HR = 1.57, 95 % CI [0.61 to
4.03]) (see Fig. 4b) alone demonstrated any significant
impact on survival. In contrast, if both nuclear LEF1 and
TCF4 (4?) were expressed, survival was significantly
shorter (p = 0.01, HR = 4.69, 95 % CI [1.23 to 17.9])
(Fig. 4c). Nuclear b-catenin expression had no significant
influence on survival (p = 0.07, HR = 0.42, 95 % CI
[0.16 to 1.09]). Furthermore, no interaction effect with
b-catenin could be found for either LEF1 or TCF4.
AXIN2 expression reflected nuclear b-catenin in lung
adenocarcinoma brain metastases
To verify our histological and immunohistochemical find-
ings, namely that expression of nuclear LEF1 and TCF4 are
associated with shorter survival and to prove possible
b-catenin independence in brain metastasis samples, we
analyzed a microarray dataset containing 19 adenocarci-
noma brain metastases of the lung. Since gene expression
of b-catenin does not reflect nuclear protein localization,
we searched for a representative marker, reflecting
b-Catenin activity. We therefore quantified the mRNA
expression of typical WNT/b-catenin-target genes, such as
AXIN2, cyclin D1 and c-myc, in 4 brain metastasis sam-
ples by means of qRT-PCR. Among these, AXIN2 corre-
lated best to nuclear b-catenin (Fig. 5a). Gene expression
of LEF1 and AXIN2 were correlated in the microarray
dataset of the adenocarcinoma brain metastases. However,
in line with our histological findings, we found no corre-
lation between LEF1 and AXIN2 gene expression
(p = 0.54, r = 0.15, 95 % CI [-0.33 to 0.56]) (Fig. 5b).
Coexpression of LEF1/TCF4 and AXIN2
with established WNT-targets differed
in cq34567erebral metastasis of lung adenocarcinomas
Subsequently, we correlated the gene expression of LEF1/
TCF4 and AXIN2 with 45 established WNT-target genes
Fig. 4 Kaplan-Meier curves illustrate that proliferation index Ki67
(a) and LEF1?/TCF4? (c) have a significant impact (Cox propor-
tional hazard ratio) on survival of brain metastasis patients, while no
impact can be shown for nuclear LEF1 alone (b). Survival is given in
months
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selected from the WNT website (see Supplemental gene
Table 1 with respective probe IDs). There was little over-
lap between these two cohorts; only a few of the selected
target genes were co-expressed concomitantly with both
genes (Fig. 6).
Nguyen and colleagues [12] demonstrated an impact of
a TCF4 as well as a WNT-lung signature on the relapse of
patients with primary lung adenocarcinomas. The authors
attributed the effect of LEF1/TCF4 to WNT/b-catenin-
signaling. To investigate the interdependency of LEF1/
TCF4 and WNT/b-catenin in more detail, we established a
LEF1/TCF4 signature as well as an AXIN2 signature, the
latter as an indicator for WNT/b-catenin-signaling (for
more details see ‘‘Materials and methods’’ section). The
LEF1/TCF4 and AXIN2 signature contained n = 13/
n = 12 genes, whereas 45/29 probe IDs of these genes
fulfilled the correlation criteria on the microarray, respec-
tively (see Supplemental List 2). Other than CD44 and
Gremlin2 (GREM2), the majority of genes were exclu-
sively represented in one of the two signatures.
LEF1/TCF4 signature defined two clusters
with difference in survival in primary lung
adenocarcinomas
To further clarify the predictive power of these two sig-
natures derived from brain metastatic tissue, we tested
these in a microarray dataset of 58 early resectable stages
of primary lung adenocarcinomas with annotated survival
(GSE 14108). Two groups of patients were defined by
clustering the gene expression profiles of the LEF1/TCF4
gene signature with significantly different survival
(p = 0.01, HR = 0.32, 95 % CI [0.12 to 0.83]) (Fig. 7).
Further significant differential genes from the microarray
data were identified between these two groups.
Only seven genes were significantly differentially reg-
ulated, among them CD44 (CD44, HPRT1, LDHA, IGF,
2BP3, B3GALT2, ACACB, ZNF207, and NFYA). More-
over, in the first cluster with poor prognosis all genes
except B3GALT2 and ACACB were up-regulated. We
then performed comparative gene set enrichment analyses
between the two LEF1/TCF4 clusters considering various
biological functions (apoptosis, adherens junction, cell
cycle, endocytosis, base excision, and nucleotide excision
repair) as well as signaling pathways (EGFR-, MAPK-,
p53- and WNT signaling) considered to be related to the
LEF/TCF family (Table 2). Adherens junction (hsa04520)
and cell cycle (hsa04110) were significantly enriched
(p \ 0.01). Within the signaling pathways, WNT and
EGFR signaling were not enriched, as opposed to p53 and
MAPK signaling. In contrast, the AXIN2 signature was not
predictive. Interestingly, none of the previously published
b-catenin- [12], TTF1- [21], TCF4- [22] or WNT-lung-
signatures [9] was able to either identify major subgroups
or to predict survival in this dataset.
Discussion
An essential function of the transcription factors LEF1/
TCF4 in cerebral metastases of lung adenocarcinomas has
been described in mouse models [9], while their clinical
relevance in humans is still unclear.
First of all, our data strongly support a role of LEF1/
TCF4 in at least one subgroup of cerebrally metastasized
adenocarcinoma patients. This subgroup is characterized
by a poor prognosis, in particular regarding both nuclear
LEF1 and high TCF4 positive (4?) patients. Additionally,
we revealed the prognostic relevance of a LEF1/TCF4
signature in primary lung adenocarcinomas in a microarray
dataset of primary lung adenocarcinomas. Independently,
we demonstrated that Ki67 expression in the metastatic
tissues, a recently established marker in early-stage pri-
mary lung cancer tissue [8], still has prognostic value in
Fig. 5 a qRT-PCR of AXIN2
in nuclear b-catenin negative
and positive samples (n = 4).
b Gene expression of LEF1 and
AXIN2 in lung cancer brain
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this late stage of the disease. Interestingly, there was a
trend in nuclear LEF1 expression to correlate with high
proliferation index Ki67. A previous study recently
demonstraded that WNT5a expression correlated with a
high proliferation index Ki67 and stromal VEGF-A
expression, leading to shorter overall survival in primary
Fig. 6 Correlations of LEF1
and AXIN2 with WNT-target
genes selected from the WNT-
website in lung cancer brain
metastases of primary
adenocarcinomas of the lung
(GSE14180) by Pearson’s
correlation test. There is no
consistent correlation pattern
between LEF1 and AXIN2 with
WNT-target gene expression
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NSCLC [23]. Interestingly, WNT5a, the typical candidate
for b-catenin-independent WNT signaling, can influence
the phosphorylation status of various LEF/TCF proteins
with effects on gene transcription [24, 25]. Another study
demonstrated a correlation of WNT1 with Ki67, c-myc,
and poor prognosis in primary NSCLC [26]. All these
findings indicate a role of WNT signaling in prognostically
unfavorable subgroups of lung cancer. Moreover, all these
findings point to cell-type or context-dependent functions
of WNT signaling in different subtypes of lung cancer.
Our data are consistent with the different derivation of
these tumors from varying cells of origin. The TTF1-neg-
ative adenocarcinomas derive from the centrally-based
cells: the bronchial basal and the mucous cells [4]. Inter-
estingly, LEF1 (-/-) mice exhibit no submucosal glands
derived from central epithelial cells [27], demonstrating a
role of LEF1 in centrally-based cell types at least in
embryonic development. In contrast, b-catenin (-/-)
knock down leads to down-regulation of differentiated
peripheral alveolar epithelial cells [28], which are the ori-
gin of the peripherally derived TTF1-positive adenocarci-
nomas. Moreover, constitutively active KRAS and
b-catenin in the peripheral Clara cells lead to more
aggressive adenocarcinomas by inducing a switch to an
embryonic progenitor phenotype, indicating a role of
b-catenin in the peripheral cells [29].
Additionally, the cell-type-dependent effects of b-cate-
nin and LEF1/TCF4 are underlined by our cluster analysis
results based on the LEF1/TCF4 signature, in which the
revealed clusters depicted diverging enrichment patterns of
the cell cycle pathway in the primaries of lung adenocar-
cinomas. Furthermore, none of the previously published
b-catenin- [12], TTF1- [21], TCF4- [22] or WNT-lung-sig-
natures [9] was able to either identify major subgroups or
to predict survival in this dataset.
This suggests a cell-type-specific function of LEF1 in
the central bronchial cells, while b-catenin seems to be
more related to the peripheral cells. This may provide an
explanation of the lacking correlation between b-catenin
and LEF1 in the adenocarcinomas and the differences in
the predictive values of the signatures.
However, this does not exclude any direct activation or
modification of LEF1/TCF4 by WNT signaling. Further
studies are needed to confirm the function of b-catenin,
LEF1 and WNT signaling in the two different peripheral
(type II pneumocytes, Clara cells) and the two central cell
types (basal and mucous) [4].
Cell-type-specific effects of b-catenin and LEF1/TCF4
were already demonstrated in other malignancies. In mel-
anoma, nuclear b-catenin correlates with better prognosis
and causes differentiation [30]. In contrast, overexpression
of mutated LEF1, lacking the DNA binding domain, results
in reduced melanoma cell motility [31]. A study in primary
colon cancer described similar discrepancies. In that study,
TCF4 overexpression was related to an unfavorable prog-
nosis [32] whereas nuclear b-catenin in late-stage colon
cancer predicted a favorable outcome [33].
Taking together the previous results in a mouse model,
the defects in embryonic development after LEF1 knock
out, and our results, these findings support the importance
of LEF1 in a subgroup of lung adenocarcinoma with
potential impact on prognosis. However, the mode of its
action remains unclear. Despite the lack of correlation with
nuclear b-catenin, it could be classical WNT/b-catenin-
Table 2 Pathway analyses of the two LEF1/TCF4 clusters in
primary lung adenocarcinomas
Pathways KEGG p value
Adherens junction Hsa04520 0.002
Apoptosis Hsa04210 0.068
Base excision repair Hsa03410 0.060
Cell cycle Hsa04110 \0.001
Endocytosis Hsa04144 0.1137
MAPK-signaling Hsa04010 \0.001
Nucleotide excision repair Hsa03420 0.026
P53-signaling Hsa04115 \0.001
WNT-signaling Hsa04310 0.083
Fig. 7 a Heatmap of the cluster analysis, based on gene expression
values of LEF1/TCF4 signature genes, leads to identification of two
separate clusters. Green bars mark survivors, black bars represent
non-survivors. b The survival analysis indicates a good prognosis for
cluster 2 compared to cluster 1 (Cox proportional hazard ratio of the
two clusters). Survival is given in months
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dependent signaling as suggested in the in vivo study.
However, it could also be b-catenin-independent LEF1 or
WNT functions [34–36], as suggested for the latter in
breast cancer brain metastasis [14, 15]. Either way,
b-catenin-independent regulations of the LEF/TCF family
members, such as stabilization, localization, and nuclear
transport [37–40] as well as their b-catenin-independent
architectural function on DNA have only rarely attracted
attention in cancer biology to date [10].
In conclusion, this retrospective study underlines the
previous results obtained in a mouse model concerning a
role of LEF1/TCF4 in brain metastasis of lung adenocar-
cinoma. Our data indicate that LEF1/TCF4, but not
b-catenin, have prognostic relevance in primary and cere-
brally metastasized human lung adenocarcinoma patients.
However, further studies are needed to highlight the sig-
nificance of our findings and to specify which signaling
pathways are involved in the LEF1/TCF4 function.
Acknowledgments The authors would like to thank Katja Schulz
and Jessica Eggert for their excellent technical assistance, David Mu
for providing us the TTF1 signature, and Marko Balkenhol from the
Go¨ttinger Comprehensive Cancer Center (G-CCC) for providing data
from the cancer registry. This work is funded by the German Research
Council (DFG) in two projects of the Forschergruppe 942 (FOR942
BI 703/3-1; BE 2552/4-1) and by the Research Program of the Faculty
of Medicine, Georg-August-University Go¨ttingen, Germany.
Conflict of interest There is no conflict of interests relating to any
of the authors.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011)
Global cancer statistics. CA Cancer J Clin 61:69–90
2. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain
RK (2011) The biology of brain metastases-translation to new
therapies. Nat Rev Clin Oncol 8:344–356
3. Steeg PS, Camphausen KA, Smith QR (2011) Brain metastases as
preventive and therapeutic targets. Nat Rev Cancer 11:352–363
4. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger
KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE,
Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti
G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Ces-
pedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J,
Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin
W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B,
Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I,
Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz
D (2011) International association for the study of lung cancer/
american thoracic society/european respiratory society international
multidisciplinary classification of lung adenocarcinoma. J Thorac
Oncol 6:244–285
5. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL
(2009) Thyroid transcription factor 1 is an independent prog-
nostic factor for patients with stage I lung adenocarcinoma. J Clin
Oncol 27:271–278
6. Barletta JA, Perner S, Iafrate AJ, Yeap BY, Weir BA, Johnson
LA, Johnson BE, Meyerson M, Rubin MA, Travis WD, Loda M,
Chirieac LR (2009) Clinical significance of TTF-1 protein
expression and TTF-1 gene amplification in lung adenocarci-
noma. J Cell Mol Med 13:1977–1986
7. Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V,
Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H, Rubin
MA (2009) TTF1 expression in non-small cell lung carcinoma:
association with TTF1 gene amplification and improved survival.
J Pathol 217:65–72
8. Oka S, Uramoto H, Shimokawa H, Iwanami T, Tanaka F (2011)
The expression of Ki-67, but not proliferating cell nuclear anti-
gen, predicts poor disease free survival in patients with adeno-
carcinoma of the lung. Anticancer Res 31:4277–4282
9. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi
M, Gerald WL, Massague J (2009) WNT/TCF signaling through
LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
Cell 138:51–62
10. Arce L, Yokoyama NN, Waterman ML (2006) Diversity of LEF/
TCF action in development and disease. Oncogene 25:7492–7504
11. Wend P, Holland JD, Ziebold U, Birchmeier W (2010) Wnt
signaling in stem and cancer stem cells. Semin Cell Dev Biol
21:855–863
12. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi
MB, Harpole D, Lancaster JM, Berchuck A, Olson JA Jr, Marks
JR, Dressman HK, West M, Nevins JR (2006) Oncogenic path-
way signatures in human cancers as a guide to targeted therapies.
Nature 439:353–357
13. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG,
Foekens JA, Martens JW (2008) Subtypes of breast cancer show
preferential site of relapse. Cancer Res 68:3108–3114
14. Klemm F, Bleckmann A, Siam L, Chuang HN, Rietkotter E,
Behme D, Schulz M, Schaffrinski M, Schindler S, Trumper L,
Kramer F, Beissbarth T, Stadelmann C, Binder C, Pukrop T
(2011) b-catenin-independent WNT signaling in basal-like breast
cancer and brain metastasis. Carcinogenesis 32:434–442
15. Pukrop T, Dehghani F, Chuang HN, Lohaus R, Bayanga K,
Heermann S, Regen T, Van RD, Klemm F, Schulz M, Siam L,
Hoffmann A, Trumper L, Stadelmann C, Bechmann I, Hanisch
UK, Binder C (2010) Microglia promote colonization of brain
tissue by breast cancer cells in a Wnt-dependent way. Glia
58:1477–1489
16. Barrett T, Edgar R (2006) Mining microarray data at NCBI’s
Gene Expression Omnibus (GEO)*. Methods Mol Biol
338:175–190
17. Cox DR (1972) Regression models and life-tables. J Roy Stat Soc
34:187–220
18. Smyth GK: Linear models and empirical bayes methods for
assessing differential expression in microarray experiments. Stat
Appl Mol Biol 2004;3
19. Kanehisa M (2002) The KEGG database. Novartis Found Symp
247:91–101
20. Beissbarth T (2006) Interpreting experimental results using gene
ontologies. Methods Enzymol 411:340–352
21. Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK,
Stevenson M, Tuchman S, Mukherjee S, Barry W, Dressman HK,
Nevins JR, Powers S, Mu D, Potti A (2009) Characterizing the
developmental pathways TTF-1, NKX2-8, and PAX9 in lung
cancer. Proc Natl Acad Sci USA 106:5312–5317
Clin Exp Metastasis (2013) 30:471–482 481
123
22. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I,
Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis
AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals
S, Eilers M, Medema R, Clevers H (2002) The beta-catenin/TCF-
4 complex imposes a crypt progenitor phenotype on colorectal
cancer cells. Cell 111:241–250
23. Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise
H, Ueno M (2005) Wnt5a expression is associated with the tumor
proliferation and the stromal vascular endothelial growth factor–
an expression in non-small-cell lung cancer. J Clin Oncol
23:8765–8773
24. Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J,
Waterman M, Shibuya H, Moon RT, Ninomiya-Tsuji J, Mat-
sumoto K (2003) The TAK1-NLK mitogen-activated protein
kinase cascade functions in the Wnt-5a/Ca(2?) pathway to
antagonize Wnt/beta-catenin signaling. Mol Cell Biol 23:131–
139
25. Kuhl M, Geis K, Sheldahl LC, Pukrop T, Moon RT, Wedlich D
(2001) Antagonistic regulation of convergent extension move-
ments in Xenopus by Wnt/beta-catenin and Wnt/Ca2?signaling.
Mech Dev 106:61–76
26. Nakashima T, Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno
M, Kadota K, Huang CL (2008) Wnt1 overexpression associated
with tumor proliferation and a poor prognosis in non-small cell
lung cancer patients. Oncol Rep 19:203–209
27. Duan D, Yue Y, Zhou W, Labed B, Ritchie TC, Grosschedl R,
Engelhardt JF (1999) Submucosal gland development in the
airway is controlled by lymphoid enhancer binding factor 1
(LEF1). Development 126:4441–4453
28. Mucenski ML, Wert SE, Nation JM, Loudy DE, Huelsken J,
Birchmeier W, Morrisey EE, Whitsett JA (2003) beta-Catenin is
required for specification of proximal/distal cell fate during lung
morphogenesis. J Biol Chem 278:40231–40238
29. Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu
MM, Demayo FJ, Morrisey EE (2011) Wnt/beta-catenin signal-
ing accelerates mouse lung tumorigenesis by imposing an
embryonic distal progenitor phenotype on lung epithelium. J Clin
Invest 121:1935–1945
30. Lucero OM, Dawson DW, Moon RT, Chien AJ (2010) A re-
evaluation of the ‘‘oncogenic’’ nature of Wnt/beta-catenin
signaling in melanoma and other cancers. Curr Oncol Rep
12:314–318
31. Murakami T, Toda S, Fujimoto M, Ohtsuki M, Byers HR, Etoh T,
Nakagawa H (2001) Constitutive activation of Wnt/beta-catenin
signaling pathway in migration-active melanoma cells: role of
LEF-1 in melanoma with increased metastatic potential. Biochem
Biophys Res Commun 288:8–15
32. Kriegl L, Horst D, Reiche JA, Engel J, Kirchner T, Jung A (2010)
LEF-1 and TCF4 expression correlate inversely with survival in
colorectal cancer. J Transl Med 8:123
33. Elzagheid A, Buhmeida A, Korkeila E, Collan Y, Syrjanen K,
Pyrhonen S (2008) Nuclear beta-catenin expression as a prog-
nostic factor in advanced colorectal carcinoma. World J Gastro-
enterol 14:3866–3871
34. Giese K, Grosschedl R (1993) LEF-1 contains an activation
domain that stimulates transcription only in a specific context of
factor-binding sites. EMBO J 12:4667–4676
35. Giese K, Pagel J, Grosschedl R (1997) Functional analysis of
DNA bending and unwinding by the high mobility group domain
of LEF-1. Proc Natl Acad Sci USA 94:12845–12850
36. Love JJ, Li X, Case DA, Giese K, Grosschedl R, Wright PE
(1995) Structural basis for DNA bending by the architectural
transcription factor LEF-1. Nature 376:791–795
37. Mallory MJ, Jackson J, Weber B, Chi A, Heyd F, Lynch KW:
Signal- and developmental-dependent alternative splicing of
LEF1 in T cells is controlled by CELF2. Mol Cell Biol 2011
38. Prieve MG, Guttridge KL, Munguia JE, Waterman ML (1996)
The nuclear localization signal of lymphoid enhancer factor-1 is
recognized by two differentially expressed Srp1-nuclear locali-
zation sequence receptor proteins. J Biol Chem 271:7654–7658
39. Prieve MG, Guttridge KL, Munguia J, Waterman ML (1998)
Differential importin-alpha recognition and nuclear transport by
nuclear localization signals within the high-mobility-group DNA
binding domains of lymphoid enhancer factor 1 and T-cell factor
1. Mol Cell Biol 18:4819–4832
40. Nawshad A, Medici D, Liu CC, Hay ED (2007) TGFbeta3
inhibits E-cadherin gene expression in palate medial-edge epi-
thelial cells through a Smad2-Smad4-LEF1 transcription com-
plex. J Cell Sci 120:1646–1653
482 Clin Exp Metastasis (2013) 30:471–482
123
